Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Dose and Schedule Finding Trial to Evaluate the Safety and Efficacy of AMG 531 for Treatment of Severe Thrombocytopenia Due to Multi-Cycle Chemotherapy in Adult Subjects With Lymphoma.

NCT00283439 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT00283439
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00283439 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Dose and Schedule Finding Trial to Evaluate the Safety and Efficacy of AMG 531 for Treatment of Severe Thrombocytopenia Due to Multi-Cycle Chemotherapy in Adult Subjects With Lymphoma.
Lead sponsor
Amgen
Phase
Phase 1/2
Overall status
Completed
Start date
October 31, 2005
Completion date
September 30, 2008
Enrollment
39 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, chemotherapy-induced thrombocytopenia, hodgkin's lymphoma, non-hodgkin's lymphoma, oncology, thrombocytopenia